JNJ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 20:30):

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...

Stats
Dagens volum	3.61M
Gjennomsnittsvolum	7.66M
Markedsverdi	352.50B
EPS	$0 ( 2024-04-16 )
Neste inntjeningsdato	( $2.73 ) 2024-07-18
Last Dividend	$1.190 ( 2023-11-20 )
Next Dividend	$0 ( N/A )
P/E	19.71
ATR14	$0.0540 (0.04%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	Broadhurst Vanessa	Sell	8 891	Common Stock
2024-03-05	Woods Eugene A.	Buy	262	Deferred Share Units
2024-03-05	Woods Eugene A.	Buy	491	Deferred Share Units
2024-03-05	Hewson Marillyn A	Buy	235	Deferred Share Units
2024-02-15	Taubert Jennifer L	Buy	76 981	Employee Stock Options (Right to Buy)

INSIDER POWER
62.63
Last 100 transactions
Buy: 859 893 \| Sell: 197 905

Volum Korrelasjon

Lang: -0.10 (neutral)

Kort: 0.03 (neutral)

Signal:(48.004) Neutral

Johnson & Johnson Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Johnson & Johnson Korrelasjon - Valuta/Råvare

-0.01
( neutral )

-0.04
( neutral )

0.00
( neutral )

-0.08
( neutral )

-0.59
( weak negative )

-0.81
( strong negative )

Johnson & Johnson Økonomi

Annual	2023
Omsetning:	$85.15B
Bruttogevinst:	$58.41B (68.60 %)
EPS:	$14.60

FY	2023
Omsetning:	$85.15B
Bruttogevinst:	$58.41B (68.60 %)
EPS:	$14.60

FY	2022
Omsetning:	$94.94B
Bruttogevinst:	$63.85B (67.26 %)
EPS:	$6.83

FY	2022
Omsetning:	$94.94B
Bruttogevinst:	$63.85B (67.26 %)
EPS:	$6.82

Financial Reports:

No articles found.

Johnson & Johnson Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.130 (N/A)	$1.130 (N/A)	$1.130 (N/A)	$1.190 (N/A)	$1.190 (N/A)	$1.190 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Johnson & Johnson Dividend Information - Dividend Knight

Dividend Sustainability Score: 2.99 - low (50.00%) | Divividend Growth Potential Score: 6.03 - Stable (20.64%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00208	1970-02-16
Last Dividend	$1.190	2023-11-20
Next Dividend	$0	N/A
Payout Date	2023-12-05
Next Payout Date	N/A
# dividends	216	--
Total Paid Out	$62.63	--
Avg. Dividend % Per Year	1.76%	--
Score	4.56	--
Div. Sustainability Score	2.99
Div.Growth Potential Score	6.03
Div. Directional Score	4.51	--

Next Divdend (Est)
(2024-07-01)

$1.200 Estimate 40.00 %

Dividend Stability

0.80 Very Good

Dividend Score

4.56

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1970	$0.00709	0.58%
1971	$0.00895	0.75%
1972	$0.00930	0.46%
1973	$0.0109	0.41%
1974	$0.0151	0.65%
1975	$0.0177	1.02%
1976	$0.0219	1.16%
1977	$0.0292	1.79%
1978	$0.0354	2.27%
1979	$0.0416	2.68%
1980	$0.0464	2.90%
1981	$0.0534	2.57%
1982	$0.0606	2.65%
1983	$0.0672	2.17%
1984	$0.0736	2.89%
1985	$0.0797	3.57%
1986	$0.0860	2.65%
1987	$0.101	2.39%
1988	$0.120	2.46%
1989	$0.140	2.68%
1990	$0.164	2.19%
1991	$0.193	2.20%
1992	$0.223	1.59%
1993	$0.253	2.04%
1994	$0.283	2.50%
1995	$0.320	2.35%
1996	$0.368	1.75%
1997	$0.425	1.71%
1998	$0.485	1.49%
1999	$0.545	1.32%
2000	$0.620	1.35%
2001	$0.700	1.37%
2002	$0.795	1.35%
2003	$0.925	1.67%
2004	$1.095	2.12%
2005	$1.275	2.03%
2006	$1.455	2.36%
2007	$1.620	2.44%
2008	$1.795	2.72%
2009	$1.930	3.18%
2010	$2.11	3.26%
2011	$2.25	3.58%
2012	$2.40	3.64%
2013	$2.59	3.66%
2014	$2.76	3.03%
2015	$2.95	2.82%
2016	$3.15	3.13%
2017	$3.32	2.87%
2018	$3.54	2.54%
2019	$3.75	2.94%
2020	$3.98	2.73%
2021	$4.19	2.68%
2022	$4.45	2.59%
2023	$4.70	2.64%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.453	1.500	0.950	1.424	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.572	1.500	4.76	7.14	[0.1 - 1]
payoutRatioTTM	0.218	-1.000	7.82	-7.82	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	24.26	1.000	2.13	2.13	[3 - 30]
operatingCashFlowPerShareTTM	8.04	2.00	7.32	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.52	2.00	6.74	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.698	1.000	1.702	1.702	[0.2 - 0.8]
operatingProfitMarginTTM	0.258	1.000	6.85	6.85	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				2.99

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.75	1.000	9.22	0	[1 - 100]
returnOnEquityTTM	0.572	2.50	6.63	7.14	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.52	2.00	7.83	10.00	[0 - 30]
dividendYielPercentageTTM	3.26	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.04	2.00	7.32	10.00	[0 - 30]
payoutRatioTTM	0.218	1.500	7.82	-7.82	[0 - 1]
pegRatioTTM	-0.0950	1.500	-3.97	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.218	1.000	7.05	0	[0.1 - 0.5]
Total Score				6.03

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.